European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Executive Summary
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
You may also be interested in...
Bronchitol Gets Final NICE OK, TOBI Podhaler Trumps Colobreathe
Pharmaxis’ Bronchitol became the first cystic fibrosis drug to get a NICE final approval, while Novartis’s TOBI Podhaler was selected ahead of Forest Lab’s Colobreathe for bacterial infection.
Extension Of Eliquis’ Indication Will See It Face Off Against Xarelto And Pradaxa In Europe
Europe’s top drug regulator recommended an additional indication for Bristol-Myers Squibb/ Pfizer’s Eliquis for AF, setting the stage there for a showdown with Bayer/J&J’s Xarelto and Boehringer Ingelheim’s Pradaxa.
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come
It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses